How many shares did Cronos repurchase in the first half of 2026?

Cronos repurchased 12.3 million shares during the six months ended June 30, 2026. The company spent $32.9 million on these repurchases, resulting in an implied average price of approximately $2.67 per share. This reduced the share count from 381.6 million at year-end 2025 to 370.7 million at mid-year 2026.

Why is Cronos actively repurchasing shares?

Management stated that it believes share repurchases represent an attractive use of capital, particularly given the company's strong balance sheet and positive operating cash flow. The buyback program allows Cronos to return capital to shareholders while maintaining financial flexibility to invest in growth, pursue acquisitions, and act on opportunistic opportunities.

What authorization governs this buyback program?

The company's current share repurchase program was authorized on May 8, 2026. The filing does not specify the total dollar or share amount authorized, the expiration date, or other terms of the May 2026 authorization, describing the program only as 'renewed' at that date.

How does the buyback impact Cronos' financial position?

The 12.3 million shares repurchased reduced the outstanding share count by approximately 3.2%, which mechanically improves per-share metrics when net income is positive. During H1 2026, Cronos generated net income of $51.4 million and positive operating cash flow of $34.9 million, meaning the repurchase activity occurred alongside strong operational performance and maintenance of $827 million in total liquidity.

Is Cronos still pursuing other capital-allocation priorities alongside buybacks?

Yes. The company is preparing to close its pending acquisition of CanAdelaar B.V. (expected in H2 2026) and continues to invest organically in its cannabis brands and international expansion, particularly in Israel and Germany. Management emphasized that the repurchase program operates within a disciplined capital-allocation framework that includes growth investments and optionality for strategic opportunities.

What was the average price paid per share?

Based on the disclosed figures, Cronos paid approximately $2.67 per share on average ($32.9 million spent / 12.3 million shares repurchased). The filing does not separately disclose per-share pricing by period or execution method.

CRON 8-K Filed 2026-08-06 Execution disclosure

Cronos Group repurchased 12.3M shares in H1 2026 under active buyback program

Cannabis firm reduces share count while achieving record revenues and positive cash generation amid disciplined capital deployment

Shares repurchased12.3M

MechanismNot specified

What the filing says

Cronos Group Inc. repurchased 12.3 million shares during the first half of 2026, according to the company's second-quarter earnings press release filed August 6, 2026. The filing confirms the company remains active under its share repurchase program, which was previously authorized on May 8, 2026. Management characterized the repurchases as an attractive use of capital in the context of an industry-leading balance sheet and positive operating cash flow.

For the six months ended June 30, 2026, Cronos spent $32.9 million on share repurchases, reflecting a reduction in share count from 381.6 million shares outstanding at December 31, 2025 to 370.7 million shares as of June 30, 2026. This 11 million net reduction in share count over the first half of 2026 contributed to the company's organic per-share financial performance improvements during a period of record net revenue ($98.2 million, +49% YoY) and positive net income of $51.4 million for the half-year period.

The company emphasized that the repurchase program operates alongside its strategic priorities, which include organic growth investments, the pending acquisition of CanAdelaar B.V., and optionality to act on attractive opportunities. Management stated the program reflects discipline in capital allocation while maintaining sufficient liquidity and financial flexibility.

We remain active under our share repurchase program and continue to believe the repurchases represent an attractive use of capital. Backed by an industry-leading balance sheet and positive cash flow from operations, we are well positioned to invest in our growth strategy while returning capital to shareholders and maintaining optionality to be opportunistic as attractive opportunities arise. — Cronos Group Inc. 8-K filing · View on SEC EDGAR →

What this means

Cronos' execution of 12.3 million share repurchases in H1 2026 reduced share count by approximately 3.2% of the opening base, directly offsetting the dilution from the company's ongoing share-based compensation programs and contributing positively to per-share metrics during a period of operational improvement. At an implied average price of approximately $2.67 per share ($32.9 million / 12.3 million shares), the buyback occurred while the company maintained $827 million in total liquidity (cash, short-term investments, and non-current deposits). The repurchase activity is consistent with management's stated view that buybacks represent an attractive capital deployment option for a cannabis producer with positive cash flow and an industry-leading balance sheet, even as the company pursues acquisition opportunities and invests in organic growth.

Frequently asked questions

How many shares did Cronos repurchase in the first half of 2026?: Cronos repurchased 12.3 million shares during the six months ended June 30, 2026. The company spent $32.9 million on these repurchases, resulting in an implied average price of approximately $2.67 per share. This reduced the share count from 381.6 million at year-end 2025 to 370.7 million at mid-year 2026.
Why is Cronos actively repurchasing shares?: Management stated that it believes share repurchases represent an attractive use of capital, particularly given the company's strong balance sheet and positive operating cash flow. The buyback program allows Cronos to return capital to shareholders while maintaining financial flexibility to invest in growth, pursue acquisitions, and act on opportunistic opportunities.
What authorization governs this buyback program?: The company's current share repurchase program was authorized on May 8, 2026. The filing does not specify the total dollar or share amount authorized, the expiration date, or other terms of the May 2026 authorization, describing the program only as 'renewed' at that date.
How does the buyback impact Cronos' financial position?: The 12.3 million shares repurchased reduced the outstanding share count by approximately 3.2%, which mechanically improves per-share metrics when net income is positive. During H1 2026, Cronos generated net income of $51.4 million and positive operating cash flow of $34.9 million, meaning the repurchase activity occurred alongside strong operational performance and maintenance of $827 million in total liquidity.
Is Cronos still pursuing other capital-allocation priorities alongside buybacks?: Yes. The company is preparing to close its pending acquisition of CanAdelaar B.V. (expected in H2 2026) and continues to invest organically in its cannabis brands and international expansion, particularly in Israel and Germany. Management emphasized that the repurchase program operates within a disciplined capital-allocation framework that includes growth investments and optionality for strategic opportunities.
What was the average price paid per share?: Based on the disclosed figures, Cronos paid approximately $2.67 per share on average ($32.9 million spent / 12.3 million shares repurchased). The filing does not separately disclose per-share pricing by period or execution method.

execution cannabis-sector share-count-reduction mid-cap organic-growth positive-cash-flow

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.